Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention

Importance

The benefits and risks associated with intensive low-density lipoprotein cholesterol (LDL-C)–lowering statin-based therapies to lessen the risk of recurrent stroke have not been established.

Objective

To conduct a meta-analysis of randomized clinical trials to evaluate the association of more intensive vs less intensive LDL-C–lowering statin-based therapies with outcomes for patients with ischemic stroke.

Data Sources

PubMed, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched from January 1, 1970, to July 31, 2021.

Study Selection

This meta-analysis included randomized clinical trials that compared more intensive vs less intensive LDL-C–lowering statin-based therapies and recorded the outcome of recurrent stroke among patients with stroke.

Data Extraction and Synthesis

The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was used for abstracting data and assessing data quality and validity. Relative risk (RR) with 95% CI was used as a measure of the association of more intensive vs less intensive LDL-C lowering with primary and secondary outcomes.

Main Outcomes and Measures

The primary outcome was recurrent stroke, and the secondary outcomes were major cardiovascular events and hemorrhagic stroke.

Results

The final analysis included 11 randomized clinical trials with 20 163 patients (13 518 men [67.0%]; mean [SD] age, 64.9 [3.7] years) with stroke. The mean follow-up was 4 years (range, 1-6.1 years). Pooled results showed that more intensive LDL-C–lowering statin-based therapies were associated with a reduced risk of recurrent stroke compared with less intensive LDL-C–lowering statin-based therapies (absolute risk, 8.1% vs 9.3%; RR, 0.88; 95% CI, 0.80-0.96) and that the benefit associated with these LDL-C–lowering therapies was not different among LDL-C–lowering strategies (statins vs no statins: RR, 0.90; 95% CI, 0.81-1.01; more statins or ezetimibe vs less statins or ezetimibe: RR, 0.77; 95% CI, 0.62-0.96; and proprotein convertase subtilisin/kexin type 9 inhibitors plus statins vs placebo plus statins: RR, 0.90; 95% CI, 0.71-1.15;P = .42 for interaction). More intensive LDL-C–lowering statin-based therapies were associated with a reduced risk of major cardiovascular events, but with an increased risk of hemorrhagic stroke, compared with less intensive LDL-C–lowering statin-based therapies. More intensive LDL-C–lowering statin-based therapies were associated with a reduced risk of recurrent stroke in trials with all patients having evidence of atherosclerosis (RR, 0.79; 95% CI, 0.69-0.91), but not in trials with most patients not having evidence of atherosclerosis (RR, 0.95; 95% CI, 0.85-1.07;P = .04 for interaction), compared with less intensive LDL-C–lowering statin-based therapies.

Conclusions and Relevance

This study suggests that the benefits and risks of more intensive LDL-C–lowering statin-based therapies for recurrent stroke risk reduction might be more favorable than the benefits and risks of less intensive LDL-C–lowering statin-based therapies, especially for patients with evidence of atherosclerosis.